Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Blake

Interventional Cardiology Lexington, KY Medical Doctor

NPI 1699702308 CMS profile 31311

1401 Harrodsburg Rd, Suite A-300, Lexington, KY 40504

Open in the dashboard

General payments

$4,960

248 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Blake of Lexington, KY is reported in the CMS Open Payments database as having received $4,960 across 248 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 38th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $538 26
2024 General $825 54
2023 General $1,003 52
2022 General $694 33
2021 General $607 21
2020 General $313 20
2019 General $981 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Blake
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Richard Blake were reported at $538. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Richard Blake Interventional Cardiology median Middle half National median
2019 $981 $1,097 $329–$3,048 $163
2020 $313 $473 $161–$1,480 $114
2021 $607 $677 $233–$1,827 $132
2022 $694 $978 $333–$2,724 $149
2023 $1,003 $1,136 $382–$2,986 $160
2024 $825 $1,181 $395–$3,326 $164
2025 $538 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $651 39 payments
  2. Janssen Pharmaceuticals, Inc $643 68 payments
  3. Novo Nordisk Inc $528 16 payments
  4. Pfizer Inc. $491 35 payments
  5. Sanofi-Aventis U.S. LLC $466 18 payments
  6. Merck Sharp & Dohme Corporation $452 23 payments
  7. Medtronic Vascular, Inc. $258 3 payments
  8. Medtronic, Inc. $226 2 payments
  9. Abiomed $210 7 payments
  10. Esperion Therapeutics, Inc. $201 5 payments
  11. Other $834 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,864 245 payments
  2. Education $97 3 payments
Products named General payments · program years 2019–2025
  1. XARELTO $839 70 payments
  2. VERQUVO $531 28 payments
  3. Ozempic $320 12 payments
  4. ELIQUIS $264 20 payments
  5. ENTRESTO Cardiology/Vascular Diseases $244 16 payments
  6. VYNDAQEL $227 15 payments
  7. PRALUENT $224 2 payments
  8. NEXLETOL $201 5 payments
  9. ENTRESTO Cardiovascular $201 12 payments
  10. LEQVIO $187 10 payments
  11. Other $2,103 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

2,938

Median for Cardiology: 2,533

Drug cost

$771,284

Median for Cardiology: $485,213

Branded share of claims

34.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 207 $221,314
Xarelto Rivaroxaban Brand 168 $177,260
Entresto Sacubitril/Valsartan Brand 132 $167,984
Jardiance Empagliflozin Brand 101 $132,768
Brilinta Ticagrelor Brand 22 $18,386
Farxiga Dapagliflozin Propanediol Brand 13 $10,162
Multaq Dronedarone Hcl Brand 11 $8,255
Janumet Sitagliptin Phos/Metformin Hcl Brand 11 $5,951
Amiodarone Hcl Generic 78 $2,894
Flecainide Acetate Generic 70 $2,505

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$68,997

Medicare's payments for the services billed

Medicare patients

1,131

Average age 74

Services billed

2,945

611 women, 520 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 41%
Ischemic heart disease 41%
Chronic kidney disease 33%
COPD 33%
Atrial fibrillation 30%
Heart failure 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $172
$172 168 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $90
$90 132 —
VERQUVO
  • Merck Sharp & Dohme Corporation $79
$79 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $66
$66 — —
VYNDAQEL
  • PFIZER INC. $65
$65 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

248 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record